Helixmith Announces First Patient Enrolled in Phase 2 Study of...

Helixmith announced today enrollment of the first patient in a new Phase 2A clinical trial, REViVALS-1A, targeting Amyotrophic Lateral Sclerosis (ALS) using Helixmith’s flagship gene therapy product...(PRWeb March 10, 2021)Read the full story at https://www.prweb.com/releases/helixmith_announces_first_patient_enrolled_in_phase_2_study_of_engensis_vm202_for_amyotrophic_lateral_sclerosis/prweb17786005.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news